WHO R&D Blueprint COVID-19
At present, there are no vaccines, no curative treatments and a strong need for more rapid diagnostic tests for COVID-19. Therefore, research is needed to accelerate timely, adequate, affordable and equitable access to these products. Switzerland supports WHO efforts to elaborate a research roadmap based on knowledge gaps for COVID-19 pandemic treatments, vaccines and related epidemiological studies, with a focus on low- and middle income countries.
Pays/région | Thème | Période | Budget |
---|---|---|---|
Monde entier |
Santé
Maladies infectieuses
Renforcement des systèmes de santé |
01.09.2020
- 31.08.2023 |
CHF 2’000’000
|
- Organisation mondiale de la santé
-
Secteur selon catégorisation du Comité d'aide au développement de l'OCDE SANTE
SANTE
Sous-Secteur selon catégorisation du Comité d'aide au développement de l'OCDE Lutte contre les maladies infectieuses
Politique de la santé et gestion administrative
Type d'aide Contribution à des projets ou programmes
Numéro de projet 7F10584
Contexte |
With the announcement by WHO on 30.01.2020 that the novel coronavirus constituted a Public Health Emergency of International Concern, a Research and Development (R&D) program for COVID-19 was activated (“WHO R&D Blueprint”). On 11-12.02.2020, WHO convened a Global Research Summit where 500+ scientists identified critical research priorities. A coordinated Global Research and Innovation Roadmap was then developed. This proposal is aligned with the priorities of this Roadmap, with a focus on treatments, vaccines and related epidemiological studies. The research roadmap with its clear priority setting in research on diagnostics, therapies and vaccines against COVID-19 is essential for Switzerland which formally participates to the trials. This support is also complementary to Switzerland’s contribution to the Coalition for Epidemic Preparedness Innovations (CEPI). |
Objectifs | Accelerate research for timely, adequate, affordable and equitable access to any innovation and medical countermeasures to those at risk of COVID-19, with a focus on LMICs. |
Groupes cibles |
Researchers and clinicians in LMICs. The global research and development community for COVID-19. Key funders and implementing partners including GAVI, CEPI, Wellcome Trust. Manufacturers, regulators and procurement agencies (UNICEF, Global Fund, etc.). Patients and population at high risk for COVID-19. |
Effets à moyen terme |
· Therapeutics Solidarity Trial[1] have identified treatments that lead to a reduction in all-cause mortality and a reduction in the duration of hospital stay. · Vaccine Solidarity Trials have identified candidate vaccines for licensure and equitable access to those at highest risk. - Solidarity epidemiological studies have generated evidence on risk factors for transmission; impact of infection prevention and control measures in health care settings; incidence of infection, viral persistence on surfaces, etc. [1] The Solidarity Trial is an international clinical trial to help find an effective treatment for COVID-19, launched by WHO and partners. It is hoped that one or more of the treatments under trial will result in improving clinical outcomes in COVID-19 patients and save lives. |
Résultats |
Principaux résultats attendus: · LMICs have participated in Solidarity trial · Collaborators in LMICs have participated - Collaborators in LMICs have joined Solidarity Principaux résultats antérieurs: Not applicable. This is a new proposal. |
Direction/office fédéral responsable |
DDC |
Crédit |
Coopération au développement |
Partenaire de projet |
Partenaire contractuel Organisme des Nations Unies (ONU) Autres partenaires Governments, NGOs, private sector |
Coordination avec d'autres projets et acteurs | GAVI, COVAX AMC and COVAX Facility, CEPI, FIND |
Budget | Phase en cours Budget de la Suisse CHF 2’000’000 Budget suisse déjà attribué CHF 2’000’000 |
Phases du projet |
Phase 1 01.09.2020 - 31.08.2023 (Completed) |